Delcath Systems, Inc. (NASDAQ:DCTH) saw a large growth in short interest during the month of July. As of July 31st, there was short interest totalling 42,417,695 shares, a growth of 31.3% from the July 14th total of 32,294,368 shares. Approximately 9.4% of the shares of the company are short sold. Based on an average daily trading volume, of 48,692,178 shares, the days-to-cover ratio is presently 0.9 days.

An institutional investor recently raised its position in Delcath Systems stock. Renaissance Technologies LLC boosted its stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH) by 167.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 160,128 shares of the medical device company’s stock after buying an additional 100,214 shares during the period. Renaissance Technologies LLC owned approximately 7.29% of Delcath Systems worth $147,000 as of its most recent SEC filing. Institutional investors and hedge funds own 0.54% of the company’s stock.

Delcath Systems (NASDAQ DCTH) opened at 0.0915 on Friday. The stock’s market capitalization is $23.08 million. The firm’s 50-day moving average is $0.15 and its 200-day moving average is $0.13. Delcath Systems has a 52-week low of $0.02 and a 52-week high of $4.31.

TRADEMARK VIOLATION WARNING: “Delcath Systems, Inc. (DCTH) Short Interest Update” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/08/11/delcath-systems-inc-dcth-short-interest-update.html.

Delcath Systems Company Profile

Delcath Systems, Inc is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS).

Receive News & Ratings for Delcath Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.